Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
Roxadustat in the treatment of anemia in chronic kidney disease patients
To evaluate the efficacy of roxadustat compared to Darbepoetin alfa in the treatment of anemia in non-dialysis dependent Chronic Kidney Disease (NDD-CKD) subjects.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
Investigation of the suitability of an alternative pretreatment - tramadol - for Qutenza. Lidocaine is currently the approved pretreatment before application of Qutenza (for the treatment of peripheral neuropathic pain). Tramadol will be tested against lidocaine
To evaluate the tolerability of QUTENZA treatment when applied after pre-treatment with topical lidocaine or oral tramadol.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
Estudio de fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (25 mg, una vez al día y 50 mg, una vez al día) en pacientes con síntomas de vejiga hiperactiva. A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder
Evaluar la eficacia de 25 y 50 mg de YM178 una vez al día frente a placebo en el tratamiento de pacientes con síntomas de vejiga hiperactiva. To assess the efficacy of YM178 25 mg qd and YM178 50 mg...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A multicenter, open-label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) with Overactive Bladder (OAB) Protocol for Phase I Study of solifenacin succinate suspension Single ascending dose PK study
To evaluate the PK of solifenacin succinate suspension after single-dose administration at different dose levels in children and adolescents with OAB.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
This is a multinational study comparing the efficacy and safety of two medicines , solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder
To evaluate the efficacy of 2 dose combinations of solifenacin and mirabegron compared to solifenacin and mirabegron monotherapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
A trial comparing combination treatment (solifenacin plus mirabegron) with one treatment alone (solifenacin)
To evaluate the efficacy of solifenacin 5 mg plus mirabegron 50 mg versus solifenacin 5 mg monotherapy
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 4 ans
Étude 2215-CL-0302 : étude de phase 3 randomisée comparant l’efficacité du gilteritinib (ASP2215) avec celle d’un placebo dans le cadre d’un traitement d’entretien à la suite d’un traitement d’induction ou de consolidation chez des patients ayant une leucémie myéloïde aiguë avec mutation ITD du gène FLT3 après une première rémission complète. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
La leucémie myéloïde aiguë (LMA) est due à la multiplication non régulée de cellules anormales, appelées blastes leucémiques, qui envahissent la moelle osseuse. Le gène FLT3 est l’un des gènes les plu...
Country
France
organs
Leucémies aiguës
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Previous
3
4
5
6
7
8
9
10
11
12